Meds & supplements › Relacorilant
Medicine
Relacorilant
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
- ( 1, 14 )
- Do not take if
- LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because LIFYORLI antagonizes the effect of glucocorticoids.
What it is used for
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Side effects, and when to stop
The following adverse reactions are discussed in more detail in other sections of the labeling:
- Neutropenia and Severe Infections.
- Adrenal Insufficiency
- Exacerbation of Conditions Treated with Glucocorticoids.
Who should not take it
LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because LIFYORLI antagonizes the effect of glucocorticoids.
Storing it
Storage and Handling
Store and dispense LIFYORLI in their original carton. Store LIFYORLI at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F).
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Relacorilant; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/relacorilant
- APA 7th
sofidex. (2026, August 3). Relacorilant. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/relacorilant
- AMA 11th
Relacorilant. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/relacorilant
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.